BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon ... oxyntomodulin analog (OPK-88006) with ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Eli Lilly launches Mounjaro in India addressing diabetes-obesity crisis. Approved by CDSCO yet high costs limit accessibility ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

Unlike many oral small-molecule GLP-1 therapies being developed—whose compounds are almost exclusively modified analogs of existing molecules such as Pfizer's Danuglipron and Eli Lilly's ...